Arrowhead's Plozasiran Shows Sustained Efficacy in Long-Term Hypertriglyceridemia Study

Event summary

  • Arrowhead Pharmaceuticals presented two-year efficacy and safety data for plozasiran in hypertriglyceridemia patients at ACC.26.
  • Median triglyceride reductions of -83% in severe HTG and -67% in general HTG were observed with no acute pancreatitis events.
  • 96% of severe HTG patients achieved TG levels below 500 mg/dL, reducing acute pancreatitis risk.
  • Arrowhead plans to submit a supplemental New Drug Application for plozasiran by year-end 2026.

The big picture

Arrowhead's long-term data positions plozasiran as a potential cornerstone therapy for hypertriglyceridemia, addressing both severe and moderate cases. The durable efficacy and safety profile could expand its market beyond the recently approved familial chylomicronemia syndrome indication. This reinforces RNA interference as a key mechanism in cardiometabolic disease treatment.

What we're watching

Regulatory Timeline
Whether Arrowhead can secure supplemental FDA approval for plozasiran by year-end 2026 as planned.
Market Expansion
How the company will position plozasiran in both severe and moderate hypertriglyceridemia markets post-approval.
Competitive Dynamics
The pace at which competitors develop similar RNA interference therapies for cardiometabolic disorders.